Mark Yarchoan
MD
Associate Professor
👥Biography 个人简介
Mark Yarchoan has contributed to understanding tumor mutational burden (TMB) and mismatch repair deficiency as biomarkers for checkpoint immunotherapy response. The FDA approval of pembrolizumab for TMB-high solid tumors (2020) and for dMMR/MSI-H solid tumors (2017) represented landmark tumor-agnostic approvals where molecular features rather than histology determined treatment eligibility — paradigm-shifting decisions for precision immunotherapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Mark Yarchoan 的研究动态
Follow Mark Yarchoan's research updates
留下邮箱，当我们发布与 Mark Yarchoan（Johns Hopkins University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment